



## OPEN ACCESS

## EDITED AND REVIEWED BY

Pankaj Pathak,  
National Institutes of Health (NIH),  
United States

## \*CORRESPONDENCE

Zun guo Du  
✉ [duzunguo@sina.com.cn](mailto:duzunguo@sina.com.cn)  
Ji Xiong  
✉ [dabenx@163.com](mailto:dabenx@163.com)

<sup>†</sup>These authors share first authorship

## SPECIALTY SECTION

This article was submitted to  
Neuro-Oncology and  
Neurosurgical Oncology,  
a section of the journal  
*Frontiers in Oncology*

RECEIVED 04 October 2022  
ACCEPTED 30 December 2022  
PUBLISHED 12 January 2023

CITATION  
Hu XM, Nie Xy, Xu Kl, Wang Y, Tang F,  
Du Zg and Xiong J (2023) Corrigendum:  
H3K27M mutation doesn't mean worse  
prognosis in old patients.  
*Front. Oncol.* 12:1061604.  
doi: 10.3389/fonc.2022.1061604

COPYRIGHT  
© 2023 Hu, Nie, Xu, Wang, Tang, Du and  
Xiong. This is an open-access article  
distributed under the terms of the [Creative  
Commons Attribution License \(CC BY\)](#). The  
use, distribution or reproduction in other  
forums is permitted, provided the original  
author(s) and the copyright owner(s) are  
credited and that the original publication in  
this journal is cited, in accordance with  
accepted academic practice. No use,  
distribution or reproduction is permitted  
which does not comply with these terms.

# Corrigendum: H3K27M mutation doesn't mean worse prognosis in old patients

Xiao Mu Hu<sup>1</sup>, Xiao yu Nie<sup>2†</sup>, Kai lun Xu<sup>3†</sup>, Yin Wang<sup>1</sup>, Feng Tang<sup>1</sup>,  
Zun guo Du<sup>1\*</sup> and Ji Xiong<sup>1\*</sup>

<sup>1</sup>Huashan Hospital, Fudan University, Shanghai, China, <sup>2</sup>Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China,

<sup>3</sup>Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

## KEYWORDS

midline glioma, H3K27M, clinicopathological study, prognosis, age

## A Corrigendum on

## H3K27M mutation doesn't mean worse prognosis in old patients

By Hu XM, Nie Xy, Xu Kl, Wang Y, Tang F, Du Zg and Xiong J (2022) *Front. Oncol.* 12:912166.  
doi: 10.3389/fonc.2022.912166

In the published article, there was an error. There was a data error in the abstract.  
A correction has been made to the Abstract, *Results*, Paragraph 1. This sentence previously stated:

"The median overall survival of H3K27M-mutant gliomas and the 80 H3K27M wild-type gliomas were both 12 months".

The corrected sentence appears below:

"The median overall survival of H3K27M-mutant gliomas and the 70 H3K27M wild-type gliomas were both 17 months".

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.